Table 4.

Sensitivity analyses tested: impact vs base-case cost; cost difference of sensitivity case.

Sensitivity scenario vs base case of $17,136 lower cost of LEN/DEX	Annual impact vs base case (favoring LEN/DEX)*	Annual net total cost difference (favoring LEN/DEX)*
Post-progression scenario: Patients initially treated with BORT switch to LEN/DEX  after relapse	$6587	($10,549)
Patient cost-sharing: 20% for office-administered therapy (BORT) and 28% for  pharmacy-dispensed therapy (LEN/DEX)32	($7574)	($24,709)
Physician reimbursement rate: Change in administration reimbursement rate for  BORT to ASP+10%	($3777)	($20,913)
Administration of subcutaneous BORT at $72.71 per administration	$2710	($14,426)
AE management: Addition of grade 2 PN for BORT (18% incidence)11	($354)	($17,490)
AE management: 28% reduction in PN through use of SC route of administration  for BORT31	$44	($17,092)
Vial wastage: 10% of BORT administrations are billed as administered rather than  full-vial quantities	$3689	($13,447)
Adjusted TTP to align comparator arms: Multiply actual TTP by ratio of TTP in  comparator arms	$2902	($14,234)

^*Numbers in parentheses indicate impact or savings in favor of LEN/DEX; numbers without parentheses indicate impact or savings in favor of BORT.

AE, adverse event; ASP, average sales price; BORT, bortezomib; DEX, dexamethasone; LEN, lenalidomide; PN, peripheral neuropathy; SC, subcutaneous.